Persisting Questions With CAR T-Cell Therapy in Multiple Myeloma

Krina K. Patel, MD, MSc, and Matthew J. Frigault, MD, address key unanswered questions surrounding the use of CAR T-cell therapy in multiple myeloma. They discuss issues such as optimal timing, durability of benefit, retreatment strategies, and combination approaches. Patel and Frigault conclude the program with an outro reflecting on how ongoing research may shape the future of CAR T-cell therapy in myeloma care.